Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 2/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23229420 | 0.80 | PTPN11 (0.38) | PTPN11NR3C1FDPSALDH1A1POLB | |
| SCHEMBL23208677 | 0.80 | KCNH2 (0.45) | PTPN11 | |
| SCHEMBL23208765 | 0.78 | PTPN11 (0.41) | PTPN11NR3C1 | |
| SCHEMBL21631557 | 0.75 | PTPN11 (0.38) | PTPN11MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL24879334 | 0.74 | ADORA3 (0.42) | LMNAALDH1A1L3MBTL1 | |
| SCHEMBL28472917 | 0.73 | FDPS (0.38) | NR3C1FDPSMEN1KMT2ALMNA | |
| SCHEMBL21631598 | 0.72 | — | — | |
| SCHEMBL21631635 | 0.72 | PTPN11 (0.41) | PTPN11 | |
| SCHEMBL21631825 | 0.72 | PTPN11 (0.41) | PTPN11 | |
| SCHEMBL21631652 | 0.70 | PTPN11 (0.36) | PTPN11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11466016-B2 | Pharmaceutical compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-10-11 | — | — | US | disclosed |
| US-20210107908-A1 | PHARMACEUTICAL COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-04-15 | — | — | US | disclosed |
| CN-111902415-A | Pharmaceutical compounds | 大冢制药株式会社 | 2020-11-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107908-A1 | PHARMACEUTICAL COMPOUNDS | MAPT, CYP3A5, SLC5A1 | PTPN11 326/4885NR3C1 1290/4885FDPS 372/4885 |
| US-11466016-B2 | Pharmaceutical compounds | MAPT, CYP3A5, SLC5A1 | PTPN11 326/4885NR3C1 1290/4885FDPS 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.